K. Beaverson

发表

Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients

V. Ricotti, C. Mansfield, Edward C Smith, 2019, Orphanet Journal of Rare Diseases.

Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents

V. Ricotti, Sharon E. Hesterlee, C. Mansfield, 2019, PloS one.

Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma.

D. Abramson, I. Dunkel, K. Beaverson, 2003, Archives of ophthalmology.

A phase II trial of carboplatin for intraocular retinoblastoma

W. Shi, J. Finlay, D. Lyden, 2007, Pediatric blood & cancer.

Systemic carboplatin for retinoblastoma: change in tumour size over time

D. Abramson, I. Dunkel, K. Beaverson, 2005, British Journal of Ophthalmology.

New retinoblastoma tumor formation in children initially treated with systemic carboplatin.

D. Abramson, I. Dunkel, Thomas C. Lee, 2003, Ophthalmology.

Rapid growth of retinoblastoma in a premature twin.

D. Abramson, A. Schefler, C. J. Kelly, 2002, Archives of ophthalmology.

Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma.

K. Choy, C. Pang, D. Lam, 2005, Neoplasia.

Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma

M. D. de Dávila, D. Abramson, I. Dunkel, 2007, Pediatric blood & cancer.

Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene.

W. Hul, J. Bollerslev, M. Whyte, 2001, Human molecular genetics.

Microsatellite instability and MLH1 promoter methylation in human retinoblastoma.

K. Choy, C. Pang, D. Lam, 2004, Investigative ophthalmology & visual science.

Fruit and Vegetable Intake during Pregnancy and Risk for Development of Sporadic Retinoblastoma

M. Orjuela, Xinhua Liu, N. Mueller, 2005, Cancer Epidemiology Biomarkers & Prevention.

Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival.

D. Abramson, H. Hochberg, Thomas C. Lee, 2003, Pediatrics.

(Neonatal) retinoblastoma in the first month of life.

D. Abramson, K. Beaverson, T. Du, 2002, Archives of ophthalmology.

Bilateral retinoblastoma, microphthalmia, and colobomas in the 13q deletion syndrome.

D. Abramson, L. Schocket, K. Beaverson, 2003, Archives of ophthalmology.

Key measurement concepts and appropriate clinical outcome assessments in pediatric achondroplasia clinical trials

KathleenW. Wyrwich, Jill Massey, H. Kitchen, 2021, Orphanet Journal of Rare Diseases.

Chorioretinal scar growth after 810-nanometer laser treatment for retinoblastoma.

Michael D. Ober, D. Abramson, M. Dinkin, 2004, Ophthalmology.

Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn.

Z. Rosenwaks, L. Veeck, D. Abramson, 2004, American journal of ophthalmology.

Patients’ and caregivers’ maximum acceptable risk of death for non‐curative gene therapy to treat Duchenne muscular dystrophy

V. Ricotti, C. Mansfield, A. Sadosky, 2021, Molecular Genetics & Genomic Medicine.

Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn.

Z. Rosenwaks, L. Veeck, D. Abramson, 2004, American journal of ophthalmology.

Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims.

A. Buikema, K. Beaverson, Rachel Schrader, 2023, Journal of managed care & specialty pharmacy.

A novel β‐thalassemia intermedia phenotype containing Nt494+129T→C and NT494+132C→A mutations in cis and a Nt168C→T (βo 39 point) mutation in trans

J. A. Heath, C. Boehm, G. Cutting, 2001 .

The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management

E. Flood, M. Lundie, E. Janssen, 2019, Expert review of pharmacoeconomics & outcomes research.